T7807

Bendazac (Bendazolic acid) is an anticataract drug. It may act by preventing protein denaturation.

Despropylene gatifloxacin, a metabolite of AM-1155, exhibits potent antibacterial activity and has favorable pharmacokinetics [1].

3-Methylglutaconic acid, a primary metabolite accumulating in 3-Methylglutaconic aciduria (MGTA), induces lipid and protein oxidation, while diminishing non-enzymatic antioxidant defenses in cerebral cortex supernatants, thereby promoting oxidative stress in the cerebral cortex. This compound is utilized in research concerning brain damage diseases [1].

HP210, a selective glucocorticoid receptor modulator (SGRM), can suppress IL-1β and IL-6 mRNA expression, suggesting its utility in investigating inflammation-related diseases [1].

Osivelotor is an allosteric modulator of hemoglobin S (HbS) [1].

GBT1118 is an orally active allosteric modulator of haemoglobin oxygen affinity, enhancing tolerance to acute severe hypoxia and suitable for hypoxia research.

E235 is a regulatory activator of transcription factor 4 (ATF4) with antiproliferative activity.E235 acts by initiating the integrated stress response (ISR) and signaling the DNA damage response.

GPR52 receptor modulator 1, a compound delineated as per Procedure 1, is a modulator of the GPR52 receptor, offering research potential in the investigation of neuropsychiatric diseases [1].

NF546 (hydrate), a selective non-nucleotide P2Y11 agonist, exhibits a pEC50 value of 6.27 and induces interleukin-8 secretion from human monocyte-derived dendritic cells [1].

Bendazac-D7 is a deuterated compound of Bendazac. Bendazac (T7807) has a CAS number of 20187-55-7. Bendazac (T7807) is an anticataract drug. It may act by preventing protein denaturation.